Helix BioPharma Files Interim Financial Statements for Q1 2026, Highlighting Oncology Pipeline Progress
Helix BioPharma Corp. has filed its unaudited interim financial statements for the three-month period ended October 31, 2025, providing transparency about its financial position while advancing clinical-stage oncology programs targeting hard-to-treat cancers.
Read the full story























